Streetbeat News

Regulatory

INDP

Indaptus Therapeutics, Inc. (NASDAQ:INDP) will present interim data from the first cohort of its Phase 1 INDP-D101 trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) on November 4, 2023. The data showed that each of the first cohort participants experienced transient activation of biomarkers associated with immune responses and expected transient adverse events, both associated with rapid clearance of Decoy20. The company is encouraged by the tolerability of Decoy20 and the evidence for broad immune biomarker activation.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 1:18 pm

GRCL

Gracell Biotechnologies Inc. (NASDAQ:GRCL) will present preclinical data from its SMART CART technology for solid tumors at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting. The technology is designed to enhance CAR-T cell proliferation and persistence in suppressive tumor microenvironments (TMEs). The company will also launch an investigator-initiated trial of SMART CART GC506 targeting Claudin 18.2 positive tumors.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 1:13 pm

SCNI

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) announced that the European Investment Bank (EIB) is considering extending the maturity of its financial facility contract with the company. This comes after Scinai's strategic shift from COVID-19 antibody development to a novel antibody for psoriasis treatment and the launch of a CDMO business unit. The potential extension could positively impact Scinai's shareholders' equity and help the company comply with Nasdaq's minimum shareholders' equity listing rules.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 1:12 pm

SPRC

SciSparc has received notice of acceptance from the Australian patent office for its patent application for Combination of Opioids and N-Acylethanolamines for pain treatment. This has led to an increase in the company's share price.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 1:11 pm

CNTX

Context Therapeutics announced preclinical data showing a differentiated and active profile of its Claudin 6-targeted bispecific antibody CTIM-76. The drug exhibits dose-proportional tumor responses and safety in preclinical models. Benchmarking studies support CTIM-76's differentiated product profile. The IND filing for CTIM-76 is on track for late Q1 2024.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 1:08 pm

MLNK

MeridianLink, Inc. (NYSE:MLNK) has announced a new integration with Experian, providing lenders with real-time access to verified income and employment information. The integration of Experian Verify with MeridianLink Consumer and Mortgage Credit Link will provide customers with enhanced capabilities that deliver a seamless digital lending experience. This move is expected to reduce risk, accelerate conversion, save money, and maintain compliance with the Fair Credit Reporting Act.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 1:08 pm

MAIA

MAIA Biotechnology has reported new results from its Phase 2 clinical trial for a treatment for non-small cell lung cancer. The data shows promising potential efficacy of the first-in-class treatment.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 1:06 pm

COEP

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) announced that research demonstrating the potential of the SNAP-CAR T-cell platform to target multiple antigens, including HER2 and CD20, will be presented at the Society for Immunotherapy of Cancer's 38th Annual Meeting (SITC 2023). The research suggests that SNAP-CAR can potentially enable the development of T-cell therapies that can be tuned by adaptor dose and targeted toward multiple antigens, potentially avoiding toxicities and relapse due to antigen loss.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 1:05 pm

VRPX

Virpax Pharmaceuticals has announced that its product, Envelta, remains on track for human trials following a review by the FDA. This suggests that the FDA has not found any significant issues that would delay the trial process.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 12:59 pm

BABA

NVDA

PDD

Alibaba's stock is trading lower amid struggles in the e-commerce sector and updates to its AI model, Tongyi Qianwen. Nvidia is set to lose billions in revenue from China due to new US sanctions on AI technology. Alibaba's cloud computing arm has launched eight AI models for various industries. Alibaba is also pressuring merchants to offer low prices for its Singles Day event, indicating rivalry with Douyin and PDD Holdings. China's state-backed chip investment fund has invested in a memory chip company, Changxin Xinqiao.

Portfolio Pulse from Anusuya Lahiri

October 31, 2023 | 12:53 pm